Compare ANNX & PKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | PKE |
|---|---|---|
| Founded | 2011 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 669.6M |
| IPO Year | 2020 | 1994 |
| Metric | ANNX | PKE |
|---|---|---|
| Price | $4.98 | $31.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 293.8K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | ★ 1.53% |
| EPS Growth | N/A | ★ 93.10 |
| EPS | N/A | ★ 0.56 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16,320.74 | N/A |
| P/E Ratio | ★ N/A | $57.24 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.85 | $13.53 |
| 52 Week High | $7.18 | $38.20 |
| Indicator | ANNX | PKE |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 43.75 |
| Support Level | $4.80 | $31.27 |
| Resistance Level | $5.07 | $35.58 |
| Average True Range (ATR) | 0.36 | 1.84 |
| MACD | -0.02 | -0.28 |
| Stochastic Oscillator | 32.19 | 14.38 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Park Aerospace Corp is an aerospace company that develops and manufactures composite materials used to produce composite structures for the aerospace market. Its products include film adhesives, lightning strike protection materials, specialty ablative materials for rocket motors and nozzles, and materials for radome applications. The Company offers composite materials designed for hand lay-up and automated fiber placement (AFP) manufacturing applications, which are used in jet engines, large and regional transport aircraft, military aircraft, unmanned aerial vehicles (UAVs), business jets, general aviation aircraft, and rotary wing aircraft. It operates in North America, Asia, and Europe, with North America generating maximum revenue.